Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience

Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors. Patients with AITL treat...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2010-12, Vol.51 (12), p.2208-2214
Main Authors: Lin, Han-Nan, Liu, Chun-Yu, Hong, Ying-Chung, Pai, Jih-Tung, Yang, Ching-Fen, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Liu, Jin-Hwang, Gau, Jyh-Pyng, Tzeng, Cheng-Hwai, Chen, Po-Min
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Angioimmunoblastic T-cell lymphoma
Female
Humans
Immunoblastic Lymphadenopathy - diagnosis
Immunoblastic Lymphadenopathy - mortality
Immunoblastic Lymphadenopathy - pathology
Immunoblastic Lymphadenopathy - therapy
Lymphoma, T-Cell - diagnosis
Lymphoma, T-Cell - mortality
Lymphoma, T-Cell - pathology
Lymphoma, T-Cell - therapy
Male
Middle Aged
peripheral T-cell lymphoma
Prognosis
Retrospective Studies
Risk Factors
survival
Survival Analysis
Taiwan
Taiwan - epidemiology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors. Patients with AITL treated at our institution from February 1988 through January 2010 were enrolled. Factors associated with overall survival (OS) were determined by statistical methods. A total of 31 Taiwanese patients (21 males) were identified. The median age was 74 years (range, 27-90). Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2010.525270